L26/P-615 Day 5/6 sequential hatching/biopsy versus day 3 hatching before blastocyst biopsy in preimplantation genetic testing: a systematic review and meta-analysis
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.945 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y. Liu und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does day 5/6 sequential blastocyst hatching/biopsy lead to different preimplantation genetic testing (PGT) and embryo transfer outcomes compared to day3 hatching before blastocyst biopsy? Summary answer Day 5/6 sequential hatching/biopsy is associated with improved outcomes following euploid blastocyst transfer compared with day 3 hatching, with an increased risk of no-PGT-result reporting. What is known already Traditionally, on day 3 an opening is created in the zona pellucida to facilitate trophectoderm biopsy on day 5/6 for PGT. However, the recent shift towards uninterrupted embryo culture has led to the adoption of a sequential approach, wherein artificial hatching is performed immediately before day 5/6 biopsy. Studies comparing these approaches have been inconclusive. The only meta-analysis addressing this question adopted a broader scope and synthesised data from one randomised control trial (RCT) and two cohort studies. As additional RCT and cohort studies have been undertaken, we aimed to conduct an updated and more focused meta-analysis on this topic. Study design, size, duration A systematic review and meta-analysis were performed according to PRISMA guidelines, with protocol registered with PROSPERO (CRD420261285930). Studies were searched for in MEDLINE, EMBASE and the Cochrane Library on 15 January 2026, using keywords ‘biopsy’ (‘trophectoderm biopsy’ or ‘blastocyst biopsy’ or ‘simultaneous biopsy’ or ‘biopsy strategy’), ‘day 3’, and ‘pre-implantation genetic testing’. RCTs and observational studies were pooled separately owing to methodological heterogeneity in study design. Participants/materials, setting, methods Two independent reviewers systematically screened and evaluated each study on patient, intervention, comparison, and outcome (PICO) data. The Newcastle-Ottawa scale was used for risk of bias assessment. Further assessment was performed by the two independent reviewers separately, with a third reviewer mediating inconsistent judgements. Data were extracted according to Cochrane methods. PGT result, post-warm survival, pregnancy and live birth data were synthesised from eligible studies depending on availability of raw data in corresponding subgroups. Main results and the role of chance Following removal of duplicates, screening according to PICO, and further eligibility assessment, two RCTs and three retrospective cohort studies were eventually included in the meta-analysis. Pooled analysis indicated that the day 5/6 sequential approach was associated with higher no-PGT-result rates compared with the day 3 approach (2 RCTs, n = 3009, OR = 5.54, 95% CI 2.98-10.31, P < 0.001, I2=68%; 2 cohort studies, n = 2612, OR = 2.91, 95% CI 1.37-6.20, P = 0.006, I2=49%). No significant differences were observed in the euploidy, aneuploidy and mosaic rates between the two approaches. However, compared with the day 3 approach, the day 5/6 sequential approach was also associated with improved post-warm survival (1 cohort study, n = 2211, OR = 5.50, 95% CI 2.79-10.85, P < 0.001), clinical pregnancy (2 RCTs, n = 486, OR = 2.05, 95% CI 1.42-2.96, P < 0.001, I2=63%; 2 cohort studies, n = 1737, OR = 1.51, 95% CI 1.25-1.83, P < 0.001, I2=0%) and live birth rates (2 RCTs, n = 486, OR = 1.86, 95% CI 1.30-2.67, P < 0.001, I2=0%; 1 cohort study, n = 1668, OR = 1.44, 95% CI 1.19-1.75, P < 0.001) following transfers of euploid blastocysts. No significant differences were observed in ongoing pregnancy (1 cohort study, n = 209, OR = 0.65, 95% CI 0.37-1.14, P > 0.05) or miscarriage rates (2 RCTs, n = 272, OR = 1.01, 95% CI 0.48-2.15, P > 0.05, I2=7%; 2 cohort studies, n = 1050, OR = 1.08, 95% CI 0.72-1.63, P > 0.05, I2=0%) between both approaches. Limitations, reasons for caution The studies included in this meta-analysis showed various heterogeneity across different outcomes. The sample sizes of the two RCTs were relatively small, particularly for analyses of pregnancy outcomes. Large well-designed RCTs are required before robust, evidence-based guidelines can be established for clinical practice. Wider implications of the findings Our results support the day 5/6 sequential hatching/biopsy approach over day 3 hatching in terms of post-warm survival and pregnancy outcomes, but not no-PGT-result rates. However, given the low clinical relevance considering its rare occurrence (0-5.7% as reported by included studies), this limitation may be outweighed by its associated benefits. Trial registration number Yes
Zitieren
APA
Liu, Y., Qi, F., & Hart, R. (2026). L26/P-615 Day 5/6 sequential hatching/biopsy versus day 3 hatching before blastocyst biopsy in preimplantation genetic testing: a systematic review and meta-analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.945
Vancouver
Liu Y, Qi F, Hart R. L26/P-615 Day 5/6 sequential hatching/biopsy versus day 3 hatching before blastocyst biopsy in preimplantation genetic testing: a systematic review and meta-analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.945
BibTeX
@article{Liu2026,
author = {Liu, Y. and Qi, F. and Hart, R.},
title = {L26/P-615 Day 5/6 sequential hatching/biopsy versus day 3 hatching before blastocyst biopsy in preimplantation genetic testing: a systematic review and meta-analysis},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.945}
}
EUVIMED